百济神州：港股公告：百济神州有限公司截至2023年12月31日止三个月未经审核业绩及2023全年经审核业绩以及业务进展最新情况
BeiGene, Ltd.
06160
2023123120231231
13.09
571XIVA
2023123120231231
2023123120231231
2024
2024226
202432820231231
1995(Private Securities LitigationReform Act of 1995)
10-K
2024226
Olivier BrandicourtMargaret Han DuganDonald W. GlazerMichael GollerAnthony C. HooperRanjeev KrishanaAlessandro RivaCorazon (Corsee) D. Sanders
2023? 20236.34
67%2574%?
?
2023
4.13135%13129%? sonrotoclax
(CLL)3BTK CDAC(R/R)CLLR/R(MCL)
?
BGNE06160688235
2023
2023
?(John V. Oyler)
? 20236.30586%
2275%? (GAAP)2023
18%33%28%47%? (FDA)
?
3ALPINE?
(R/R)(CLL)(PFS)29.6
?
BTK?
?
R/R(FL)
BTK? 202312(ASH)25
o ALPINE39
??
R/R CLLPFSo sonrotoclax 1/2
?
CLLsonrotoclax
R/Rsonrotoclax
t(11,14)(MM)
o BTK CDAC(BGB-16673)
BBTKBTK CDAC
? PD-1
?(EMA)(CHMP)(NSCLC)(ESCC)
EMA10
? 20235(NMEs)
CDK4BGB-43395202320236.34425
3.80114
2023
3.13211
1.5545.026
?
2024
123112312023202220232022$ 630,526$ 339,022$ 2,189,852$ 1,254,612$ 3,883$ 41,073$ 268,927$ 161,309$ 634,409$ 380,095$ 2,458,779$ 1,415,921GAAP $ (383,795)$ (468,622)$ (1,207,736)$ (1,789,665)
*$ (267,224)$ (372,480)$ (752,473)$ (1,420,225)* GAAP(GAAP)
GAAPGAAP
20236.30522
3.39013
?
?20234.13013
1.7615.647
?
?
20231.2805.366
1.0224.229
? 20235,110
1.8832,7701.146202383.2%82.7%
78.3%77.2%
???
20232022
GAAPGAAP20232022
(%)
20232022
(%)$ 493,987$ 446,02311%$ 437,383$ 404,1868%$ 416,547$ 328,98427%$ 361,435$ 275,64831%
(1)
$ 1,838$ 188878%$ –$ –$ 912,372$ 775,19518%$ 798,818$ 679,83418%
20232022
GAAPGAAP20232022(%)20232022(%)$ 1,778,594$ 1,640,5088%$ 1,558,960$ 1,474,9196%$ 1,504,501$ 1,277,85218%$ 1,284,689$ 1,077,97719%
(1)
$ 3,500$ 751366%$ –$ –$ 3,286,595$ 2,919,11113%$ 2,843,649$ 2,552,89611%
(1) 20231231
2023GAAP2023
3,1804,6804,8706,870
(SG&A)2023GAAPSG&A
?
2023GAAP
BMS3.62920230.27(ADS)
3.530.33ADS4.2920230.65ADS8.45
1.49ADS19.43
123120232022$ 3,875,037$ 4,382,887
(1,157,453)(1,496,619)
60,0041,077,123416,478(18,971)(8,082)(69,383) (689,053)(507,850)
$ 3,185,984$ 3,875,03720232.21612
3.18215
2023
202310-K
?
?
(PFS)R/R(FL)BTK?
?
? SonrotoclaxCLL3BTK CDAC
?
? FDA
3ALPINER/R CLL/SLLPFS?
R/RFL? 4R/R
(TN)CLL
?
?
(NMPA)?
(MHRA)
ESCC? EMA CHMP
NSCLC?
(ES-SCLC)(sBLA)
NMPA?
IIIIIA(NSCLC)
NMPA? ESCC
EMA
?
? ASH3ALPINE
??
R/R CLL/SLLPFS?
NSCLC1Sonrotoclax (BGB-11417)
? FDA
(MM)(WM)(AML)
(MCL)?
?CLL? ASHsonrotoclax
o
?TN CLLo
t(11,14)MMBCL-2o R/R MZL
BTK CDAC (BGB-16673)
? ASH
BBTKBTK CDAC? R/R MCL
? FDA
R/R MCL
LBL-007 LAG3
?
ESCC
? (NME)BGB-43395
CDK41
?
?
FDAR/R FL
BTK? FDAESCC
?
? 202436
FDANMPA
R/R FL
? 2024
FDAESCC? FDA
ESCC
(PDUFA)20247? 2024EMA
NSCLC? 2024
NMPA
ES-SCLC? 2024
NMPA
(G/GEJ)?
? 2024EMA
2024FDA? 2024
(PMDA)ESCC? 2024
EMA
G/GEJZanidatamab
? Jazz Pharmaceuticals
Zymeworks2024
NMPAHER2
(BLA)
Sonrotoclax? 2024
R/R MCL TIGIT
? 2024
3AdvanTIG-302
NSCLCTarlatamab
DLL3CD3
T
? 2024
? 202410
KRASMTAPRMT5EGFRCDK2ADC?
2024xaluritamigAMG 509STEAP1CD3XmAb
? T
Jazz/Zymeworks
XmAb
?Xencor
?
2024781009.3
?
55.95.210
? 6.5
(ADC)25
2.3171.6
? CDK2
12311231
20232022
$ 3,188,584$ 4,540,288
358,027173,168416,122282,3461,324,154845,946$ 5,805,275$ 6,379,290$ 315,111$ 294,781
693,731467,352
300255,887238,666293,960885,984538,1172,267,9481,995,935$ 3,537,327$ 4,383,355
ADSADS
123112312023202220232022
$ 630,526$ 339,022$ 2,189,852$ 1,254,612
3,88341,073268,927161,309634,409380,0952,458,7791,415,921105,83273,522379,920286,475528,577306,5732,078,8591,129,446493,987446,0231,778,5941,640,508416,547328,9841,504,5011,277,8521,8381883,500751912,372775,1953,286,5952,919,111(383,795)(468,622)(1,207,736)(1,789,665)
16,27418,21974,00952,48016,74919,438307,891(223,852)(350,772)(430,965)(825,836)(1,961,037)
16,78114,37055,87242,778(367,553)(445,335)(881,708)(2,003,815)$ (0.27)$ (0.33)$ (0.65)$ (1.49) 1,353,005,0581,348,916,1081,357,034,5471,340,729,572 ADS$ (3.53)$ (4.29)$ (8.45)$ (19.43)
ADS 104,077,312103,762,778104,387,273103,133,044
(GAAP)GAAPGAAPGAAPGAAPGAAP
GAAPGAAP
GAAP
GAAPGAAP
GAAPGAAP
GAAPGAAPGAAP
GAAPGAAP
GAAPGAAP
123112312023202220232022GAAPGAAP$ 105,832$ 73,522$ 379,920$ 286,475
1,898–8,578–1,1197813,7393,225$ 102,815$ 72,741$ 367,603$ 283,250GAAPGAAP$ 493,987$ 446,023$ 1,778,594$ 1,640,508
39,42434,966163,550139,348
17,1806,87156,08426,241$ 437,383$ 404,186$ 1,558,960$ 1,474,919GAAPGAAP$ 416,547$ 328,984$ 1,504,501$ 1,277,852
53,32843,160204,038163,814
1,78410,17615,77436,061$ 361,435$ 275,648$ 1,284,689$ 1,077,977GAAPGAAP912,372775,1953,286,5952,919,111
92,75278,126367,588303,16218,96417,04771,85862,302
1,8381883,500751$ 798,818$ 679,834$ 2,843,649$ 2,552,896GAAPGAAP$ (383,795)$ (468,622)$ (1,207,736)$ (1,789,665)
92,75278,126367,588303,16220,86217,04780,43662,302
2,9579697,2393,976$ (267,224)$ (372,480)$ (752,473)$ (1,420,225)
10,000www.beigene.com.cn
1995(Private Securities LitigationReform Act of 1995)
10-K
+86 10 5895 8058+86 21 31591070ir@ beigene.com media@ beigene.com
?
Pharmacyclics LLC